Stem cell-based therapy for myopic maculopathy: a new concept
Journal of Translational Genetics and Genomics · 2022
DOI: 10.20517/jtgg.2021.48 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Translational Genetics and Genomics, 2022. Verfasst von Ya Ma und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Myopia has reached epidemic proportions in the world, especially in East Asia. Pathologic myopia is an extreme type of high myopia that can cause irreversible blindness. Myopic maculopathy is one of the characteristics of pathologic myopia. Nowadays, limited treatments can preserve the visual outcome of these patients. We review the current treatment in practice for myopic maculopathy. Furthermore, based on the current stem cell-based therapy used in degenerative ocular diseases, we discuss a new concept of stem cell therapy for myopic maculopathy.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ma, Y., Li, Y., & Jin, Z. (2022). Stem cell-based therapy for myopic maculopathy: a new concept. Journal of Translational Genetics and Genomics. https://doi.org/10.20517/jtgg.2021.48
Vancouver
Ma Y, Li Y, Jin Z. Stem cell-based therapy for myopic maculopathy: a new concept. Journal of Translational Genetics and Genomics. 2022. doi:10.20517/jtgg.2021.48
BibTeX
@article{Ma2022,
author = {Ma, Ya and Li, Yan-Ping and Jin, Zi-Bing},
title = {Stem cell-based therapy for myopic maculopathy: a new concept},
journal = {Journal of Translational Genetics and Genomics},
year = {2022},
doi = {10.20517/jtgg.2021.48}
}
EUVIMED